The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 Treatment Recommendations for Psoriatic Arthritis

2015 Treatment Recommendations for Psoriatic Arthritis

April 28, 2016 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Psoriatic arthritis (PsA), a disease characterized by inflammatory arthritis, enthesitis, dactylitis and spondylitis in patients with psoriasis, is remarkably diverse in presentation and course. To assist the clinician in the management of PsA, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a global association of more than 500 rheumatologists, dermatologists and patient research partners, previously (in 2009) published treatment recommendations based on a systematic evidence review published in 2006. To maintain clinical relevance, such recommendations must be dynamic, requiring reevaluation and appropriate modification over time. In PsA, significant recent developments in pathophysiology and disease assessment, particularly regarding the important contribution of comorbidities coupled with major therapeutic advances, necessitated an update of the GRAPPA recommendations. For example, several new compounds had been approved since the 2006 literature review, and further evidence on existing therapies has accumulated.

You Might Also Like
  • New Guideline for the Treatment of Psoriatic Arthritis
  • 2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications
  • Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes

The authors present overarching principles and updated treatment recommendations for the key manifestations of PsA. The recommendations were developed to provide up-to-date systematic and evidence-based guidance for the treatment and management of PsA in adults. The recommendations are not specifically relevant for patients with juvenile idiopathic arthritis or psoriasis only. The target audience for these GRAPPA recommendations is anyone involved in the treatment of patients with PsA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Six overarching principles for the care of patients with PsA were developed after extensive feedback. There was ≥80% agreement among GRAPPA members who responded to the survey (135 healthcare providers and 10 patient research partners) for all of these principles, within both the group of healthcare providers and the group of patient research partners. These principles include the following:

  • The ultimate goals of therapy for all patients with PsA are: 1) To achieve the lowest possible level of disease activity in all domains of disease; as definitions of remission and low or minimal disease activity become accepted, these will be included in the goal. 2) To optimize functional status, improve quality of life and well-being, and prevent structural damage to the greatest extent possible. 3) To avoid or minimize complications, both from untreated active disease and from therapy.
  • Assessment of patients with PsA requires consideration of all major disease domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease. The impact of disease on pain, function, quality of life, and structural damage should be examined. In addition, activity in other potential related conditions should be considered. Multidisciplinary and multispecialty assessment and management will be most beneficial for individual patients.
  • A comprehensive assessment of relevant comorbidities (including but not restricted to obesity, metabolic syndrome, gout, diabetes, cardiovascular disease, liver disease, depression and anxiety) should be undertaken and documented.
  • Therapeutic decisions need to be individualized and are made jointly by the patient and his or her doctor.
  • Ideally, patients should be reviewed promptly, offered regular evaluation by appropriate specialists and have treatment adjusted as needed in order to achieve the goals of therapy. Early diagnosis and treatment are likely to be of benefit.

The recommendations for PsA therapies by disease domain are summarized in the table below.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Arthritis & Rheumatology, Clinical Practice Guidelines, GRAPPA, Guidelines, Psoriatic Arthritis

You Might Also Like:
  • New Guideline for the Treatment of Psoriatic Arthritis
  • 2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications
  • Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.